← All Carisma Therapeutics INC filings

Carisma Therapeutics INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

OTC.Pink
CARM
Carisma Therapeutics INC
DEFA14A: Carisma Seeks Reverse Split to Maintain Nasdaq Listing
Carisma Therapeutics Inc. seeks stockholder approval for a reverse stock split to meet Nasdaq listing requirements and facilitate its merger with OrthoCellix.
OTC.Pink
CARM
Carisma Therapeutics INC
DEF: Carisma Therapeutics Seeks Reverse Stock Split to Avoid Nasdaq Delisting and Facilitate Merger
Carisma Therapeutics Inc. is holding a special stockholder meeting on August 5, 2025, to vote on a reverse stock split aimed at regaining Nasdaq compliance and meeting conditions for its proposed merger with OrthoCellix, Inc.
OTC.Pink
CARM
Carisma Therapeutics INC
DEF 14A: Carisma Therapeutics Sets Date for 2024 Annual Stockholder Meeting, Outlines Key Proposals
Carisma Therapeutics announces its 2024 annual meeting of stockholders to be held virtually on June 13, 2024, featuring proposals for director elections, executive compensation advisory vote, and ratification of KPMG LLP as the independent auditor.